NasdaqCM - Nasdaq Real Time Price USD

Compass Therapeutics, Inc. (CMPX)

2.1400
-0.0100
(-0.47%)
At close: June 3 at 4:00:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for CMPX

Recent News: CMPX

View More
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire 6 days ago
Spotlight On Three Promising Penny Stocks In May 2025

Spotlight On Three Promising Penny Stocks In May 2025
Simply Wall St. 20 days ago
Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update
GlobeNewswire 26 days ago
Compass Therapeutics to Participate in Upcoming May Investor Events

Compass Therapeutics to Participate in Upcoming May Investor Events
GlobeNewswire 28 days ago
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire last month
Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer
GlobeNewswire last month
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
GlobeNewswire 2 months ago
Compass Therapeutics And 2 More Compelling Penny Stocks

Compass Therapeutics And 2 More Compelling Penny Stocks
Simply Wall St. 2 months ago
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
GlobeNewswire 2 months ago
Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer
GlobeNewswire 2 months ago
With 42% stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) seems to have captured institutional investors' interest

With 42% stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) seems to have captured institutional investors' interest
Simply Wall St. 2 months ago
View More

Related Tickers

CNTX Context Therapeutics Inc.
0.5820
-1.02%
 
GHRS GH Research PLC
12.08
+4.50%
 
RZLT Rezolute, Inc.
4.4200
+4.62%
 
SVRA Savara Inc.
2.4000
0.00%
 
CLYM Climb Bio, Inc.
1.2900
+9.32%
 
STOK Stoke Therapeutics, Inc.
10.90
+9.99%
 
TCRX TScan Therapeutics, Inc.
1.7500
+19.86%
 
BCYC Bicycle Therapeutics plc
8.30
-2.92%
 
ACRS Aclaris Therapeutics, Inc.
1.4700
+2.08%
 
RLAY Relay Therapeutics, Inc.
3.2900
+3.46%